Directorio de personas
Diego Arango Del Corro

Diego Arango Del Corro

Grado: Doctor/a


darango(ELIMINAR)@irblleida.cat

ResearcherID: http://www.researcherid.com/rid/M-5667-2016

Publicaciones

  • Matos AI; Carreira B; Peres C; Moura LIF; Conniot J; Fourniols T; Scomparin A; Martínez-Barriocanal Á; Arango D; Conde JP; Préat V; Satchi-Fainaro R; Florindo HF

    Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer.

    JOURNAL OF CONTROLLED RELEASE 307 108-138. .

    [doi:10.1016/j.jconrel.2019.06.017]

  • Gener P; Rafael D; Seras-Franzoso J; Perez A; Pindado LA; Casas G; Arango D; Fernández Y; Díaz-Riascos ZV; Abasolo I; Schwartz S

    Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells.

    Cancers 11 -. .

    [doi:10.3390/cancers11081058]

  • Rafael D; Gener P; Andrade F; Seras-Franzoso J; Montero S; Fernández Y; Hidalgo M; Arango D; Sayós J; Florindo HF; Abasolo I; Schwartz S; Videira M

    AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against cancer stem cells.

    DRUG DELIVERY 25 961-972. .

    [doi:10.1080/10717544.2018.1461276]

  • Gener P; Seras-Franzoso J; Callejo PG; Andrade F; Rafael D; Martínez F; Montero S; Arango D; Sayós J; Abasolo I; Schwartz S

    Dynamism, Sensitivity, and Consequences of Mesenchymal and Stem-Like Phenotype of Cancer Cells.

    Stem Cells International 2018 4516454-4516454. .

    [doi:10.1155/2018/4516454]

  • Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M

    Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.

    MOLECULAR ONCOLOGY 12 1383-1397. .

    [doi:10.1002/1878-0261.12332]

  • Tögel L; Nightingale R; Wu R; Chüeh AC; Al-Obaidi S; Luk I; Dávalos-Salas M; Chionh F; Murone C; Buchanan DD; Chatterton Z; Sieber OM; Arango D; Tebbutt NC; Williams D; Dhillon AS; Mariadason JM

    DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.

    SCIENTIFIC REPORTS 8 1767-1767. .

    [doi:10.1038/s41598-018-20176-9]

  • Dopeso H; Rodrigues P; Bilic J; Bazzocco S; Cartón-García F; Macaya I; de Marcondes PG; Anguita E; Masanas M; Jiménez-Flores LM; Martínez-Barriocanal Á; Nieto R; Segura MF; Schwartz S; Mariadason JM; Arango D

    Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer.

    BRITISH JOURNAL OF CANCER 118 106-116. .

    [doi:10.1038/bjc.2017.420]

  • Mateo-Lozano S; Bazzocco S; Rodrigues P; Mazzolini R; Andretta E; Dopeso H; Fernández Y; Del Llano E; Bilic J; Suárez-López L; Macaya I; Cartón-García F; Nieto R; Jimenez-Flores LM; de Marcondes PG; Nuñez Y; Afonso E; Cacci K; Hernández-Losa J; Landolfi S; Abasolo I; Ramón Y Cajal S; Mariadason JM; Schwartz S; Matsui T; Arango D

    Loss of the EPH receptor B6 contributes to colorectal cancer metastasis.

    SCIENTIFIC REPORTS 7 43702-43702. .

    [doi:10.1038/srep43702]

  • Andretta E; Cartón-García F; Martínez-Barriocanal Á; de Marcondes PG; Jimenez-Flores LM; Macaya I; Bazzocco S; Bilic J; Rodrigues P; Nieto R; Landolfi S; Ramon Y Cajal S; Schwartz S; Brown A; Dopeso H; Arango D

    Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer.

    SCIENTIFIC REPORTS 7 41576-41576. .

    [doi:10.1038/srep41576]

  • Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM

    Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.

    MOLECULAR CANCER THERAPEUTICS 15 1217-1226. .

    [doi:10.1158/1535-7163.MCT-15-0724]

  • Gener P; Rafael DF; Fernández Y; Ortega JS; Arango D; Abasolo I; Videira M; Schwartz S

    Cancer stem cells and personalized cancer nanomedicine.

    Nanomedicine 11 307-320. .

    [doi:10.2217/nnm.15.200]

  • Gener P; Gouveia LP; Sabat GR; de Sousa Rafael DF; Fort NB; Arranja A; Fernández Y; Prieto RM; Ortega JS; Arango D; Abasolo I; Videira M; Schwartz S

    Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells.

    Nanomedicine-Nanotechnology Biology and Medicine 11 1883-1892. .

    [doi:10.1016/j.nano.2015.07.009]

Proyectos

  • Antioxidant treatment as a novel therapeutic option for microvillus inclusion disease. ARMED
  • Nueva estrategia terapéutica para ael cáncer gástrico basada en la modulación de la señalización de RHOA
  • Desarrollo de nanosistemas de marcaje de CXCR4 mediante radiosondas para la imagen molecular de células tumorales y del microambiente tumoral
  • Identificación de nuevos biomarcadores de respuesta a los compuestos regorafenib y TAS-102 en pacientes con cáncer colorrectal.
  • Targeting tumor microevironment by a translational multivalent nanomedicine: towards an effective anticancer combination immunotherapy